Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19 Post author: Post published:October 24, 2023 Post category:uncategorized Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. You Might Also Like Precision medicine approach improves treatment for soft tissue sarcomas May 7, 2025 New mechanism disables antibiotic resistance and cross-protection in bacteria April 21, 2026 Study provides valuable insights into the evolutionary dynamics of hepatitis E virus January 23, 2024
Study provides valuable insights into the evolutionary dynamics of hepatitis E virus January 23, 2024